Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bioxis Pharmaceuticals
Lyon, Auvergne-Rhône-Alpes, Francebioxis.com ↗
- Ownership
- Private
- Employees
- ~23
- Development stage
- Other
01
Overview
Bioxis Pharmaceuticals is developing innovative regenerative medical products, including the pre-clinical monophasic tissular inductor MTI12 based on proprietary chitosan technology. Its hyaluronic acid-based dermal filler line, CYTOSIAL, has been launched commercially with exclusive distribution agreements in Europe and Asia. The company focuses on improving outcomes in dermatology and aesthetic medicine through advanced biomaterials
- Therapeutic areas
- OtherDermatology
- Modalities
- Biomaterial scaffoldChitosan-based medical deviceHyaluronic acid-based dermal filler
- Industry
- Therapeutic Medical Devices
02
Partnerships
Exclusive distribution agreements for CYTOSIAL in Europe and Asia
Beyond the preview
Go deeper on Bioxis Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bioxis Pharmaceuticals.